BUSINESS IN IRELAND
INNOVATION
INVEST IN IRELAND
IDA IRELAND
LOCATIONS

GlaxoSmithKline

GSK, one of the largest pharmaceutical companies in the world, established a manufacturing facility in Cork in 1975. Since then, Ireland has become a location for repeat investments by GSK in major manufacturing expansions and significant R&D

“The deciding factors which resulted in the Cork operation being the location of choice …were the excellent work of the existing R&D team, the dedication and commitment of the workforce which has resulted in the consistent success of the facility, our proven experience in project management and the support of the Irish Government through IDA Ireland”. Finbar Whyte, Vice-President, GSK Cork

At a Glance

GlaxoSmithKline (GSK) is one of the largest pharmaceutical companies in the world with leadership in three major therapeutic areas – anti-infectives, central nervous system and respiratory.

It was formed through the December 2000 merger of British drugmakers Glaxo Wellcome and SmithKlineBeecham. Headquartered in London, it employs over 101,000 people worldwide and has an extensive global sales and marketing network with product supplied from 78 sites in 37 countries.
 

GlaxoSmithKline in Ireland

GSK employs 1,450 people in Ireland and first established operations here in 1975. It has two manufacturing operations in Dungarvan and is the largest employer in the town with almost 700 staff; it has a third manufacturing operation, where it develops and produces a range of bulk pharmaceuticals, together with R&D and European Trading operations in Cork; and in Dublin there are Sales and Marketing functions.

Cork – a strategic global new product introduction site

Established in 1974, the Cork plant is a strategic global new product introduction site within GSK’s manufacturing network and is currently the sole production site for a number of the Group’s top selling drugs such as Seroxat which is an anti-depressant, Avandia which addresses Type 2 diabetes and Coreg which treats serious heart conditions.

€250 million investment in Cork production site

GlaxoSmithKline (GSK) is to invest up to €250 million over five years in its production site at Currabinny, Co. Cork to manufacture products, including the active ingredient for TYKERB® (lapatinib), a new oral treatment for advanced breast cancer. The investment is supported by IDA Ireland and will create up to 150 new high level positions.

Dungarvan – base for two manufacturing plants

GSK has two manufacturing plants based in Dungarvan, Co. Waterford. One is a global pharmaceutical manufacturing facility engaged in the production of a range of over the counter pharmaceuticals. Products include Panadol, Coldrex, Solpadeine and Panadol Extra. The second is an oral care facility manufacturing products such as dental fixative and denture cleaning tablets.

€30 million manufacturing expansion in Dungarvan

GSK has two manufacturing plants in Dungarvan, Co. Waterford. A global pharmaceutical manufacturing facility establish in 1987 engaged in the production of over the counter (OTC) pharmaceuticals and smoking cessation products.

In January 2007, GSK announced an expansion involving €23m investment to increase capacity for the introduction of new Panadol products. A further expansion of its OTC site was announced in April 2008 with the addition of smoking cessation products to Dungarvan’s manufacturing remit. This involves a €30 million investment and 50 new jobs.

An oral care facility manufacturing products such as dental fixative and denture cleaning tablets, established since 1981.
 

GSK Trading Services, Cork

Established in 1974, the Cork plant is a strategic global new product introduction site within GSK for bulk pharmaceuticals. Over €60 million has been invested in R&D on this site. This includes a chemical pilot plant, an R&D laboratory for research into the physical properties of active pharmaceutical ingredients and a pharmaceutical R&D pilot facility.

GSK Trading Services, Cork

GSK Trading Services Ltd (GSKTS) was established in 2006 in Cork. Activities include:

  • Intercompany and third party cross-border invoicing and support.
  • VAT administration associated with above.
  • Tolled and non-tolled stock accounting.
  • Acquisition integrated for supply chain and financial elements.


Research and Development Activities
GSK is investing up to €13.7m in the establishment of a ground breaking research project into gastrointestinal diseases, in collaboration with Alimentary Pharmabiotic (APC) in UCC.

Benefits of locating in Ireland Global base for pharmaceutical Research and Development

Ireland’s commitment to creating a base for global pharmaceutical R&D was a vital element in GSK’s decision to invest €34 million for R&D at the Cork plant.

How Ireland’s benefits GlaxoSmithKline
  •  Ireland’s Pharmaceutical Professionals

The Irish Government’s ongoing investment in the pharmaceutical sector has created a bank highly skilled pharmaceutical professionals and technicians. This has provided a strong resource for the GSK’s future development of pharmaceutical and healthcare products.

  • Supply Chain Management

Ireland’s experience in pharmaceutical manufacturing and the supply of active ingredients and finish products has contributed to ongoing efficiencies for GSK worldwide.

  • Manufacturing

Ireland’s commitment to the highest pharmaceutical manufacturing standards helps to ensure that GSK’s Irish sites meet and exceed international criteria.
 

E-mail to a friend   |   Print page